Studies on the Cytotoxicity and Anticancer Performance of Heterocyclic Hypervalent Organobismuth(iii) Compounds.

Yong-Ping Liu,Jian Lei,Li-Wen Tang,Yao Peng,Chak-Tong Au,Yi Chen,Shuang-Feng Yin
DOI: https://doi.org/10.1016/j.ejmech.2017.08.043
IF: 7.088
2017-01-01
European Journal of Medicinal Chemistry
Abstract:Novel organobismuth(III) complex of 5H-dibenzo[c,f][1,5]oxabismocin-12(7H)-yl nitrate (C2) was synthesized and characterized by spectral and elemental analysis. It was compared with other five C,E,C-chelating (E = N, O, S) organobismuth(III) complexes against human adenocarcinoma alveolar basal epithelial cells (A549), human liver cancer cell line (SMCC7721), human gastric cancer cell line (SGC-7901), human colon adenocarcinoma cell line (SW480) and healthy human bronchial cell line (16HBE14o-) in vitro. It was found that C2 exhibited the best anticancer activity. Further mechanistic investigation indicated that toxicological activity of C2 was ascribable to apoptosis rather than anti-proliferative activity. Apoptosis was induced through up-regulating the level of Bcl-2/Bax as well as the activation of caspase-3. The results demonstrate that heterocyclic organobismuth(III) complexes of this type have great potential in the treatment of cancer.
What problem does this paper attempt to address?